Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

29+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 493 450 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 6 602 445 EUR· until 2029. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spanyolország· EU contribution 3 613 288 EUR· until 2028. máj.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 1 996 250 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norvégia· EU contribution 7 984 441 EUR· until 2027. aug.· 6 countries

5 of 6 running projects, newest first. Listed amounts together: 23,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Frissítve: 2026. jan. 21.

  “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Forrás

• Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Attentive interpretable tabular learning (TabNet) for miRNA expression classification in cervical cancer and Alzheimer's disease.

  BMC Bioinformatics, 2026. okt.

• A hybrid deep learning framework for automated treatment planning in cervical cancer radiotherapy.

  J Appl Clin Med Phys, 2026. okt.

• MCOD: a memory-constrained deep learning framework for robust outlier detection in quantitative proteomics.

  Brief Bioinform, 2026. szept.

• Diagnostic performance of artificial intelligence models trained on scattered single-cell images is not preserved for hyperchromatic crowded cell groups in cervical cytology.

  Cancer Cytopathol, 2026. szept.

• A Multimodal Graph Neural Network Based on MRI Radi-omics for Prognostic Prediction in Locally Advanced Cervical Squamous Cell Carcinoma.

  Cancer Control, 2026. aug.

• A novel deep learning segmentation and multimodal radiomics approach for radiation proctitis prediction in cervical cancer.

  Radiat Oncol, 2026. aug.

• From synthesis to clinic: a task-specific framework for CT images metal artifact reduction in cervical brachytherapy.

  Radiat Oncol, 2026. aug.

• Enhanced Diagnosis of Cervical Cancer Using Archer Fish Hunting Optimizer-Optimized Xception Network with AI Interpretability via Grad-CAM.

  Asian Pac J Cancer Prev, 2026. aug.

• A prospective development and evaluation of a 2D convolutional neural network-based auto-segmentation model for cervical cancer radiotherapy.

  J Egypt Natl Canc Inst, 2026. júl.

• Deep learning reconstruction-applied PROPELLER diffusion-weighted imaging in uterine malignancies: a comparison study with MUSE.

  Jpn J Radiol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.